Thromb Haemost 2005; 93(01): 8-16
DOI: 10.1160/TH04-07-0453
Review Article
Schattauer GmbH

Prevention of cardiovascular disease in type-2 diabetes: How to improve the clinical efficacy of aspirin

Virgilio Evangelista
1   Laboratory of Vascular Biology and Pharmacology, Consorzio Mario Negri Sud, S. Maria Imbaro, Chieti, Italy
,
Licia Totani
1   Laboratory of Vascular Biology and Pharmacology, Consorzio Mario Negri Sud, S. Maria Imbaro, Chieti, Italy
,
Serenella Rotondo
1   Laboratory of Vascular Biology and Pharmacology, Consorzio Mario Negri Sud, S. Maria Imbaro, Chieti, Italy
,
Roberto Lorenzet
2   “Antonio Taticchi“ Unit of Cellular and Molecular Biology of Coagulation Consorzio Mario Negri Sud, S. Maria Imbaro, Chieti, Italy
,
Gianni Tognoni
3   Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro, Chieti, Italy
,
Giorgia De Berardis
3   Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro, Chieti, Italy
,
Antonio Nicolucci
3   Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro, Chieti, Italy
› Author Affiliations
Further Information

Publication History

Received 28 July 2004

Accepted after revision 11 October 2004

Publication Date:
14 December 2017 (online)

Preview

Summary

Atherosclerotic cardiovascular disease and its thrombotic complications are the principal causes of morbidity and mortality in patients with type-2 diabetes.Aspirin reduces the risk of thrombotic events in a broad range of patients with vascular disease and, in selected individuals, is beneficial for primary prevention. Although recommended by existing guidelines,in secondary and in primary prevention trials the clinical efficacy of low-dose aspirin in patients with diabetes appears to be substantially lower than in individuals without diabetes. In this review, we discuss possible mechanisms that may contribute to reduce the antithrombotic activity of aspirin in diabetes.We also discuss adjuvant therapies used in diabetic patients that may potentially improve the antithrombotic efficacy of aspirin.